SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-055676
Filing Date
2020-12-01
Accepted
2020-12-01 07:30:14
Documents
12
Period of Report
2020-12-01
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K agle-8k_20201201.htm   iXBRL 8-K 40188
  Complete submission text file 0001564590-20-055676.txt   173896

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA agle-20201201.xsd EX-101.SCH 5764
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20201201_lab.xml EX-101.LAB 20229
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20201201_pre.xml EX-101.PRE 12077
5 EXTRACTED XBRL INSTANCE DOCUMENT agle-8k_20201201_htm.xml XML 3689
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 201359789
SIC: 2834 Pharmaceutical Preparations